Video

Early Treatment for Myelodysplastic Syndrome: Many Patients Are Missing Out

Many patients with myelodysplastic syndrome are not receiving early treatment.

About two-thirds of patients with myelodysplastic syndrome (MDS) are not being given early treatment, according to Christopher Cogle, M.D., a professor of Medicine at the University of Florida Health.

Cogle was involved with a study that examined which patients were more likely to be treated with Vidaza (azacitidine), Dacogen (decitabine) or Revlimid (lenalidomide). While he initially thought that age and frailness would be the factors that were associated with not being treated, he actually found that it was patients with higher-risk disease, private insurance and genetic testing who were more likely to be prescribed one of the three agents.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.